Spiro Compound Crystal Forms for Stable Factor D Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no small molecule inhibitors available for complement factor D targeting the complement alternative pathway, which is a key driver of complement-driven renal diseases, and existing pharmaceutical forms are limited in variety and effectiveness.
Innovation Solution
Development of crystal forms of a nitrogen-containing spiro compound with specific X-ray powder diffraction patterns and thermal properties, including crystal forms I and II, which exhibit good stability, inhibitory activity on complement factor D, and high in vivo exposure and oral bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If small molecule inhibitors of complement factor D are developed, then therapeutic options for complement-driven renal diseases are expanded, but pharmaceutical forms suitable for drug use are currently limited
Solution Approach 1:
The patent applies parameter changes by developing multiple crystal forms (Form I, Form II, and amorphous form) of the same small molecule compound. Each crystal form has distinct physical and chemical properties including solubility, stability, and bioavailability characteristics. This allows optimization of pharmaceutical formulations for different therapeutic needs while using the same active ingredient, thereby expanding therapeutic options without requiring development of entirely new compounds.
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining the small molecule complement factor D inhibitors with various excipients and formulation components. The different crystal forms are integrated into suitable pharmaceutical matrices that enhance stability and bioavailability, effectively creating composite drug products that address the limitation of available pharmaceutical forms.
2Ease of manufacture
If multiple crystal forms are developed, then pharmaceutical suitability is improved, but complexity of characterization and quality control increases
Solution Approach 1:
The patent segments the characterization process by establishing distinct identification criteria for each crystal form. Specific X-ray powder diffraction (XRPD) patterns are defined for Crystal Form I and Crystal Form II, allowing clear differentiation and identification. This segmentation approach simplifies quality control by providing form-specific fingerprints rather than requiring comprehensive analysis of all possible properties for each form.
Solution Approach 2:
The patent uses parameter changes in physical properties to differentiate crystal forms and simplify characterization. Each crystal form has characteristic XRPD patterns with specific peak positions and intensities that serve as identification parameters. This approach transforms the complexity of characterizing multiple crystal forms into a straightforward process of matching observed patterns against predefined forms with known characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms demonstrate effective inhibition of complement factor D, showing good stability and high bioavailability, offering potential therapeutic benefits for complement factor D-mediated diseases.
Implementation Method 1
small molecule inhibitors of complement factor D targeting the complement alternative pathway
Implementation Method 2
X-ray powder diffraction patterns
Implementation Method 3
X-ray powder diffraction patterns comprising diffraction peaks
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed in the present invention are crystal forms of a nitrogen-containing spiro compound, a preparation method therefor and the use thereof. Provided in the present invention is a crystal form I of a nitrogen-containing spiro compound as shown in formula A, which crystal form I has an X-ray powder diffraction pattern comprising diffraction peaks at 5.67±0.20°, 11.37±0.20°, 16.69±0.20°, 17.32±0.20° and 19.73±0.20° 2θ, as determined by using Cu-Kα radiation. Provided in the present invention is a crystal form II of the nitrogen-containing spiro compound as shown in formula A, which crystal form II has an X-ray powder diffraction pattern comprising diffraction peaks at 11.32±0.20°, 11.70±0.20°, 11.93±0.20°, 18.03±0.20°, 18.81±0.20° and 19.17±0.20° 2θ, as determined by using Cu-Kα radiation. The crystal forms of the nitrogen-containing spiro compound of the present invention have good stability, an inhibitory activity on complement factor D, a good inhibitory effect on rabbit erythrocyte hemolysis, and relatively high in-vivo exposure and relatively high oral bioavailability.